News and Announcements
Rapid Response Revival makes significant Board appointment and signs a mandate with a US Investment Bank as Lead Manager for the planned IPO in October
- Published January 11, 2021 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Rapid Response Revival Research Limited has appointed Greg Bodkin, a member of Cochlear’s senior executive team, as a Non-Executive Director to the Board.
Greg Bodkin has functional responsibility within Cochlear for new product industrialisation, procurement, manufacturing and logistics, enabling the technologies in design and development to be supplied as commercial products into global markets.
Greg brings to the board 30 years of experience in Operations and Supply Chain Management in Class 3 Medical Devices and his working knowledge and experience of how to implement, grow and manage a complex global supply chain that supports supply of a medical device will be hugely valuable to RRR.
Know more about Greg Bodkin’s bio on the Cochlear corporate webpage via this link.
With an eye towards the IPO planned for October this year, Rapid Response Revival Research Limited has executed a mandate with a US Investment Bank to be a lead manager and underwriter to the issue. This mandate includes working with RRR to provide leadership in any private capital raising rounds, as required in the lead up to the IPO.
The IB is ranked No.1 in Healthcare Investment Banking in the US, and has completed over 200 transactions in companies in the Medical Device, Diagnostic Tools, and Life Sciences sectors over the last 2 years.
About Rapid Response Revival Research Limited
Rapid Response Revival are the innovators behind the CellAED® defibrillator technology – transforming everyday people into heroes.
Sudden Cardiac Arrest (SCA) has an extremely high death rate and is a leading cause of death globally, accounting for more deaths than many cancers, influenza, car accidents and house fire deaths combined. Anyone can suffer from SCA, regardless of age, gender or fitness level – including children. The current survival rate is just 2-11%.
The CellAED® is designed to assist everyday people and medical professionals to prevent many unnecessary deaths. It is a lightweight, affordable, and personal Automated External Defibrillator (AED) solution, targeting the current government and enterprise market as well as the personal and home AED market.
Company Updates
Forget Startups: Why Magnetic Alliance is Betting on “Boring” Mid-Market Turnarounds
While Australia’s venture capital scene spent years chasing unprofitable tech startups and speculative high-growth plays, Mark Lim was quietly taking a radically different path. The Managing Partner of Magnetic Alliance Capital sees the nation’s richest investment opportunities hiding in plain sight: inside thousands of unglamorous, profitable, but operationally sluggish mid-market businesses. Speaking on Wholesale Investor’s […]
The asset class where the market has no vote
Litigation funding returns are decided in a courtroom, not a cycle. Knightsbridge’s Head of Capital is careful to call that a different risk rather than a lower one, and his answer to it is spread, not concentration. Most alternative assets still answer to something. Property answers to rates. Private credit answers to defaults. Even the […]
The listing fee vendors pay whether the house sells or not
Australia’s property portals collect more than $2 billion a year while national listings sit flat. An Australian-built AI platform is targeting the economics, not just the interface. An Australian vendor listing a home pays a vendor-paid advertising fee on top of agency commission. Rama Dwarapudi, Founder and Chief Executive Officer of RealSearch, puts a typical […]
Backed By Leading Investment Groups and Family Offices
